Venus Remedies Limited (VENUSREM.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹1,461.80 (+4.09%) as of
Key statistics
- Market cap
- 19.56B
- P/E (TTM)
- 16.82
- EPS (TTM)
- 86.91
- Dividend yield
- 0.71%
- 52-week range
- 432.10 – 2,044.30
- Beta
- 0.33
- Revenue (TTM)
- 8.11B
- Profit margin
- 14.32%
- Volume
- 37.50k
About Venus Remedies Limited
Venus Remedies Limited engages in the pharmaceutical business in India, Latin America, Europe, the Middle East, Africa, Asia, and internationally. The company is involved in the research and development of solutions focusing on antimicrobial resistance, oncology, skin and wound care, and pain management. It also provides analgesic, analgesic and antipyretic, antibiotic, antidiabetic anticoagulant, antiemetic, antiviral, cardiac, cardiovascular, CNS, disinfectant and antiseptic, gastro therapy, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, mucolytic, muscle relaxant, neurology, respiratory, stress reliver, urology, vitamins, nutrients, minerals, and solvent products, as well as herbal medicine. The company was incorporated in 1989 and is headquartered in Panchkula, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Panchkula, India
- Employees
- 1,472
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.